REGULAR CONTENT
Final ID
420
Type
Original Scientific Research-Oral or Pos
Authors
F Boas1, A Gonzalez Aguirre1, G Srimathveeravalli1, L Rund2, R Schwind3, L Schook2, J Erinjeri1, S Solomon1, H Yarmohammadi1
Institutions
1Memorial Sloan Kettering Cancer Center, New York, NY, 2University of Illinois, Urbana, IL, 3University of Illinois Cancer Center, Chicago, IL
Purpose
To develop a porcine model of pancreatic cancer, which can be used to test new locoregional therapies.
Materials & Methods
Adenovirus carrying the Cre-recombinase gene (AdCre) was injected into the pancreas of an Oncopig, which is a transgenic pig with Cre-inducible p53 and Kras mutations (5 sites in 2 pigs). Alternatively, AdCre was incubated in vitro with a pancreatic fine needle aspirate (2 sites in 2 pigs) or core biopsy (2 sites in 1 pig), then injected back into the same pig (subcutaneous or intra-pancreatic). Tumor growth was monitored by contrast-enhanced CT.
Results
Injection of AdCre directly into the pancreas resulted in tumors at 0 of 5 sites. In vitro incubation of AdCre and a pancreatic fine needle aspirate resulted in tumors at 0 of 2 sites. In vitro incubation of AdCre and a pancreatic core biopsy resulted in tumor at 2 of 2 sites (one pancreatic and one subcutaneous). Core biopsy of the subcutaneous mass showed a spindle cell sarcoma. The pancreatic tumor grew to 3.7 cm, 16 days after tumor induction. The mass was hypovascular relative to pancreas on both arterial and portal venous phase CT. However, there was no dilation of the pancreatic duct. The mass was not visible on celiac angiogram, but was visible on selective catheter angiography of the branch of the splenic artery supplying the mass.
Conclusions
Pancreatic cancer can be induced in a transgenic pig. This should enable testing of experimental ablation and intra-arterial therapies for pancreatic cancer.
Final ID
420
Type
Original Scientific Research-Oral or Pos
Authors
F Boas1, A Gonzalez Aguirre1, G Srimathveeravalli1, L Rund2, R Schwind3, L Schook2, J Erinjeri1, S Solomon1, H Yarmohammadi1
Institutions
1Memorial Sloan Kettering Cancer Center, New York, NY, 2University of Illinois, Urbana, IL, 3University of Illinois Cancer Center, Chicago, IL
Purpose
To develop a porcine model of pancreatic cancer, which can be used to test new locoregional therapies.
Materials & Methods
Adenovirus carrying the Cre-recombinase gene (AdCre) was injected into the pancreas of an Oncopig, which is a transgenic pig with Cre-inducible p53 and Kras mutations (5 sites in 2 pigs). Alternatively, AdCre was incubated in vitro with a pancreatic fine needle aspirate (2 sites in 2 pigs) or core biopsy (2 sites in 1 pig), then injected back into the same pig (subcutaneous or intra-pancreatic). Tumor growth was monitored by contrast-enhanced CT.
Results
Injection of AdCre directly into the pancreas resulted in tumors at 0 of 5 sites. In vitro incubation of AdCre and a pancreatic fine needle aspirate resulted in tumors at 0 of 2 sites. In vitro incubation of AdCre and a pancreatic core biopsy resulted in tumor at 2 of 2 sites (one pancreatic and one subcutaneous). Core biopsy of the subcutaneous mass showed a spindle cell sarcoma. The pancreatic tumor grew to 3.7 cm, 16 days after tumor induction. The mass was hypovascular relative to pancreas on both arterial and portal venous phase CT. However, there was no dilation of the pancreatic duct. The mass was not visible on celiac angiogram, but was visible on selective catheter angiography of the branch of the splenic artery supplying the mass.
Conclusions
Pancreatic cancer can be induced in a transgenic pig. This should enable testing of experimental ablation and intra-arterial therapies for pancreatic cancer.